The European Medicines Agency announced, on Tuesday, that it has received an application to license the “AstraZeneca – Oxford” vaccine against the emerging corona-virus, indicating that it may take a decision on it on January 29.
The Amsterdam-based agency stated, in a statement, that it had “received a request to allow conditions to market the vaccine against Corona developed by AstraZeneca and the University of Oxford.”
The agency approved the “Pfizer – Biontech” vaccine on December 21, and the “Moderna” vaccine on January 6, which prompted the European Commission to immediately give the green light to distribute them.
The European Medicines Agency indicated that it would conduct a rapid audit of the vaccine, with the possibility of issuing its decision on January 29, if all the data it received was “robust and complete” enough.
The European Union and the European Medicines Agency are facing pressure to accelerate the approval of new vaccines against the Corona virus, at a time when the epidemic has reached more than 620,000 deaths across the continent.
The President of the European Commission, Ursula von der Leyen, welcomed the submission of a license application for the “AstraZeneca-Oxford” vaccine, describing it as “good news”.
“As soon as the vaccine receives a positive scientific response, we will work as quickly as possible to allow it to be used in Europe,” von der Leyen wrote in a tweet on Twitter.